Cassava is advancing simufilam through a pivotal ... Eisai and Biogen have recently reported long-term data on their therapy, Leqembi (lecanemab), which showed that it is able to reduce cognitive ...

Despite the apparent failure of its most advanced experimental therapy, the company is not giving up. “Cassava will continue to review all of the data and evaluate next steps. We plan to share ...

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the end. The Austin, Texas-based biotech revealed that simufilam failed its ...

There are some instructive parallels to Cassava's current predicament. Axovant Sciences pivoted from Alzheimer's to gene therapy following the 2017 failure of intepirdine. However, despite having ...